BibTex RIS Cite

Nasopharyngeal/nasal type NK/T lymphoma: Analysis of 23 cases and current review of the literature

Year 2012, Volume: 22 Issue: 5, 275 - 283, 01.11.2012

Abstract

Objectives: This study aims to identify the presenting symptoms, treatment and outcome of patients with nasal natural killer T NK/T -cell lymphoma and to find possible differences in survival based on Ann-Arbor stage and international prognostic index IPI . Patients and Methods: Computed tomography and biopsy results of 23 patients 15 males, 8 females; mean age 41 years; range 22 to 72 years with extranodal NK/T-cell lymphoma who were treated at the department of clinical hematology between 1995 and 2011 were retrospectively analyzed. Results: The median time from onset of clinical symptoms to histological diagnosis was five months. Most patients presented with nasal obstruction 69% and rhinism 52% . The site of extranodal NK/T-cell lymphoma primarily involved nasal cavity in 39%. Orbital extension was observed in 26%. Lymphomas were classified as stage IE in 30.4%, stage IIE in 47.8% and stage IVE in 21.7%. Nineteen patients received treatment: 10 received chemotherapy plus radiotherapy, nine received chemotherapy only. We used several regimens of chemotherapy including some protocols containing etoposid, L-asparaginase and others without this drugs. Univariate analysis showed that lower IPI score, low Ann-Arbor stage and responsiveness to treatment with both chemotherapy and radiotherapy were significant factors influencing both OS and PFS. Conclusion: Nasal type NK/T-cell lymphoma showed a poor response to the conventional anthracycline-based chemotherapy, thereby an investigation for a novel therapy is urgently needed to improve survival.

Nazofarengeal/nazal tip NK/T lenfomaları: 23 olgunun analizi ve güncel literatür incelemesi

Year 2012, Volume: 22 Issue: 5, 275 - 283, 01.11.2012

Abstract

Amaç: Bu çalışmanın amacı, nazal doğal katil T hücreli NK/T lenfoma olan hastalarda semptom, tedavi ve sonuçları belirlemek ve Ann-Arbor evre ve uluslararası prognostik indeks IPI temelinde muhtemel farklılıkları saptamaktır.Hastalar ve Yöntemler: Ekstranodal NK/T hücreli lenfoma olan ve 1995-2011 yılları arasında klinik hematoloji bölümünde tedavi edilen 23 hastanın 15 erkek, 8 kadın; ort. yaş 41 yıl; dağılım 22-72 yıl bilgisayarlı tomografi ve biyopsi sonuçları retrospektif olarak değerlendirildi.Bulgular: Klinik semptomların başlangıcından histolojik tanıya kadar geçen medyan süre beş aydı. Hastaların birçoğunda burun tıkanıklığı %69 ve genizden konuşma %52 şikayeti vardı. Ekstranodal NK/T hücreli lenfoma, hastaların %39’unda nazal kavite tutulumluydu. Hastaların %26’sında orbital ekstansiyon görüldü. Lenfoma hastaların %30.4’ünde evre IE; %47.8’inde evre IIE ve %21.7’sinde evre IVE olarak sınıflandırıldı. On dokuz hasta tedavi edildi; bunların 10’una kemoterapi artı radyoterapi; dokuzuna yalnızca kemoterapi uygulandı. Bir kısmı etoposid, L-asparaginaz içeren protokoller, bir kısmi ise bu ilaçları kapsamayan protokollerden oluşan çeşitli kemoterapi rejimleri kullanıldı. Tek değişkenli analiz düşük IPI skoru, düşük Ann-Arbor evresi ve hem kemoterapi hem de radyoterapiye yanıt verme durumunun, OS ve PFS’yi etkileyen önemli faktörler olduğunu gösterdi.Sonuç: Nazal tip NK/T hücreli lenfoma, konvansiyonel antrasiklin bazlı kemoterapiye kötü yanıt verdiği için, sağkalımı iyileştirmek için yeni bir tedavinin araştırılması gerekmektedir

There are 0 citations in total.

Details

Primary Language English
Journal Section Research Article
Authors

Yosra Ben Youssef This is me

Iheb Bougmiza This is me

Zahreddine Bouabid This is me

Bechir Achour This is me

Haifa Regaieg This is me

Badreddine Sriha This is me

Malek Belkadhi This is me

Halima El Omri This is me

Abderrahim Khelif This is me

Publication Date November 1, 2012
Published in Issue Year 2012 Volume: 22 Issue: 5

Cite

APA Youssef, Y. B., Bougmiza, I., Bouabid, Z., Achour, B., et al. (2012). Nasopharyngeal/nasal type NK/T lymphoma: Analysis of 23 cases and current review of the literature. The Turkish Journal of Ear Nose and Throat, 22(5), 275-283.
AMA Youssef YB, Bougmiza I, Bouabid Z, Achour B, Regaieg H, Sriha B, Belkadhi M, Omri HE, Khelif A. Nasopharyngeal/nasal type NK/T lymphoma: Analysis of 23 cases and current review of the literature. Tr-ENT. November 2012;22(5):275-283.
Chicago Youssef, Yosra Ben, Iheb Bougmiza, Zahreddine Bouabid, Bechir Achour, Haifa Regaieg, Badreddine Sriha, Malek Belkadhi, Halima El Omri, and Abderrahim Khelif. “Nasopharyngeal/Nasal Type NK/T Lymphoma: Analysis of 23 Cases and Current Review of the Literature”. The Turkish Journal of Ear Nose and Throat 22, no. 5 (November 2012): 275-83.
EndNote Youssef YB, Bougmiza I, Bouabid Z, Achour B, Regaieg H, Sriha B, Belkadhi M, Omri HE, Khelif A (November 1, 2012) Nasopharyngeal/nasal type NK/T lymphoma: Analysis of 23 cases and current review of the literature. The Turkish Journal of Ear Nose and Throat 22 5 275–283.
IEEE Y. B. Youssef, I. Bougmiza, Z. Bouabid, B. Achour, H. Regaieg, B. Sriha, M. Belkadhi, H. E. Omri, and A. Khelif, “Nasopharyngeal/nasal type NK/T lymphoma: Analysis of 23 cases and current review of the literature”, Tr-ENT, vol. 22, no. 5, pp. 275–283, 2012.
ISNAD Youssef, Yosra Ben et al. “Nasopharyngeal/Nasal Type NK/T Lymphoma: Analysis of 23 Cases and Current Review of the Literature”. The Turkish Journal of Ear Nose and Throat 22/5 (November 2012), 275-283.
JAMA Youssef YB, Bougmiza I, Bouabid Z, Achour B, Regaieg H, Sriha B, Belkadhi M, Omri HE, Khelif A. Nasopharyngeal/nasal type NK/T lymphoma: Analysis of 23 cases and current review of the literature. Tr-ENT. 2012;22:275–283.
MLA Youssef, Yosra Ben et al. “Nasopharyngeal/Nasal Type NK/T Lymphoma: Analysis of 23 Cases and Current Review of the Literature”. The Turkish Journal of Ear Nose and Throat, vol. 22, no. 5, 2012, pp. 275-83.
Vancouver Youssef YB, Bougmiza I, Bouabid Z, Achour B, Regaieg H, Sriha B, Belkadhi M, Omri HE, Khelif A. Nasopharyngeal/nasal type NK/T lymphoma: Analysis of 23 cases and current review of the literature. Tr-ENT. 2012;22(5):275-83.